克唑替尼治疗ALK阳性晚期非小细胞肺癌患者的疗效观察

BACKGROUND AND OBJECTIVE: The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. METHODS: Twenty-eight patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14).Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily.Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m(2)) every three weeks and every patient was treated at least 3 period.Then clinical efficacy was observed after 12 mo followed-up. RESULTS: Effective rate of patients in the crizotinib group was 64.29%.It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026).The stable rate of patients in the crizotinib group was 85.71%.It was significantly higher than that of the chemotherapy group 40.86% (χ(2)=5.600, P=0.018).Median progression free survival (PFS) of the crizotinib group was 7.0 mo.It was longer than that of the chemotherapy group (4.0 mo)(P=0.002). CONCLUSION: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced ALK positive non-small cell lung cancer.The median PFS of patients is shorter.It can improve the quality of life about patients.